Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Short-term Investments (2021 - 2024)

Universe Pharmaceuticals' Short-term Investments history spans 4 years, with the latest figure at $1.4 million for Q3 2024.

  • For Q3 2024, Short-term Investments rose 0.79% year-over-year to $1.4 million; the TTM value through Sep 2024 reached $1.4 million, up 0.79%, while the annual FY2024 figure was $1.4 million, 0.79% up from the prior year.
  • Short-term Investments for Q3 2024 was $1.4 million at Universe Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $13.7 million in Q3 2021 and bottomed at $1.4 million in Q3 2023.
  • The 4-year median for Short-term Investments is $7.3 million (2022), against an average of $7.4 million.
  • The largest annual shift saw Short-term Investments plummeted 89.6% in 2023 before it grew 0.79% in 2024.
  • A 4-year view of Short-term Investments shows it stood at $13.7 million in 2021, then decreased by 4.2% to $13.1 million in 2022, then tumbled by 89.6% to $1.4 million in 2023, then grew by 0.79% to $1.4 million in 2024.
  • Per Business Quant, the three most recent readings for UPC's Short-term Investments are $1.4 million (Q3 2024), $1.4 million (Q3 2023), and $13.1 million (Q3 2022).